AlphaMark Advisors LLC Has $1,592,000 Stake in Genocea Biosciences, Inc. (GNCA)
AlphaMark Advisors LLC held its position in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA) during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 304,886 shares of the biotechnology company’s stock at the end of the second quarter. AlphaMark Advisors LLC owned about 1.07% of Genocea Biosciences worth $1,592,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Ameriprise Financial Inc. increased its position in shares of Genocea Biosciences by 34.1% in the first quarter. Ameriprise Financial Inc. now owns 19,933 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 5,068 shares during the period. Keybank National Association OH purchased a new position in shares of Genocea Biosciences during the first quarter valued at $147,000. JPMorgan Chase & Co. purchased a new position in shares of Genocea Biosciences during the first quarter valued at $217,000. FMR LLC increased its position in shares of Genocea Biosciences by 0.4% in the first quarter. FMR LLC now owns 4,274,804 shares of the biotechnology company’s stock valued at $26,033,000 after buying an additional 18,574 shares during the period. Finally, Segantii Capital Management Ltd purchased a new position in shares of Genocea Biosciences during the first quarter valued at $160,000. Institutional investors and hedge funds own 59.25% of the company’s stock.
Genocea Biosciences, Inc. (NASDAQ:GNCA) traded up 1.96% during mid-day trading on Wednesday, reaching $4.69. 40,836 shares of the company traded hands. The company’s market capitalization is $134.25 million. Genocea Biosciences, Inc. has a 52-week low of $3.28 and a 52-week high of $7.29. The stock has a 50 day moving average price of $4.86 and a 200-day moving average price of $5.49.
Genocea Biosciences (NASDAQ:GNCA) last issued its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by $0.08. Analysts expect that Genocea Biosciences, Inc. will post ($1.98) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “AlphaMark Advisors LLC Has $1,592,000 Stake in Genocea Biosciences, Inc. (GNCA)” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.watchlistnews.com/alphamark-advisors-llc-has-1592000-stake-in-genocea-biosciences-inc-gnca/1532045.html.
GNCA has been the subject of several analyst reports. Zacks Investment Research upgraded shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $6.75 target price for the company in a research note on Tuesday, May 16th. Needham & Company LLC raised shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Monday, July 24th. ValuEngine raised shares of Genocea Biosciences from a “sell” rating to a “hold” rating in a report on Monday, July 24th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $18.00 price target (up from $17.00) on shares of Genocea Biosciences in a report on Tuesday, July 25th. Finally, Cowen and Company reaffirmed an “outperform” rating and issued a $40.00 price target on shares of Genocea Biosciences in a report on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $16.52.
In other news, CFO Jonathan Poole sold 45,000 shares of the stock in a transaction on Monday, July 24th. The stock was sold at an average price of $6.00, for a total transaction of $270,000.00. Following the sale, the chief financial officer now directly owns 84,247 shares of the company’s stock, valued at approximately $505,482. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 6.70% of the company’s stock.
About Genocea Biosciences
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.